Latest Research And Development News

Enlitic delivered its strongest quarter yet with A$5.1 million in contracts, including significant agreements with Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health, while improving cash flow and advancing its AI-powered Ensight platform.

Ardea Resources is progressing its Kalgoorlie Nickel Project’s Definitive Feasibility Study with strong financial and strategic support from a Japanese Consortium and government export banks, aiming to secure a major nickel-cobalt supply chain.

Parkway Corporate Limited delivered a record $5.21 million quarterly revenue and $0.73 million EBITDA in Q3 FY26, driven by ramp-up of a major water infrastructure project. Meanwhile, its flagship Queensland Brine Management Complex progresses through key development application milestones with public notification underway.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

Strategic Elements Ltd (ASX:SOR) advanced its Energy Ink™ technology and commenced a pilot deployment of its EdgeiQ system at a WA gold mine, while maintaining a solid cash position of A$2.87 million and no debt.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.